- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Appeals court ruling upholds Lilly's Evista patents
September 1, 2010
Bloomberg NewsEli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic
version of the Evista osteoporosis treatment before March 2014.
MoreAfter health reform, Lilly looking for more
September 1, 2010
J.K. WallThe health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives
of the
bill—and calling for further government efforts to help pharmaceutical research and development.
MoreLilly wins ban of generic Strattera pending appeal
August 31, 2010
Bloomberg NewsThe U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly's request to prevent sales until
the court rules on a judge's decision invalidating a patent on the medicine.
MoreA half-century later, Indiana Landmarks returns to roots
August 28, 2010
Cory Schouten
Bankrolled by yet another multimillionaire, the historic preservation group is preparing to move into a new headquarters
in Old Centrum, a former church now undergoing a big renovation.
Lilly wins further delay in sales of Strattera copies
August 26, 2010
Bloomberg NewsStrattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would
translate into an average $1.22 million in sales.
MoreDiabetes research pioneer Kirtley dies at 96
August 25, 2010
Associated PressDiabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a
groundbreaking Eli Lilly researcher.
MoreLilly woes take notch out of debt rating
August 25, 2010
J.K. WallEven with debt levels at Eli Lilly and Co. at paltry lows, a string of bad news finally forced Standard & Poor’s
to lower
its rating on the company’s senior unsecured debt. But the New York-based agency said it believes the Indianapolis-based
drugmaker will eventually break its string of bad luck on developing new products.
MoreLilly gains panel's backing to expand Cymbalta use
August 19, 2010
Bloomberg NewsOutside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis
of studies in lower back pain and osteoarthritis of the knee.
MoreLilly wins temporary ban on sales of Strattera copies
August 19, 2010
Bloomberg NewsThe invalidation of Lilly's Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug,
which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
MoreLilly Alzheimer's drug prospect only the latest to fail
August 18, 2010
Bloomberg NewsA dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
MoreBad news piles up for Lilly
August 18, 2010
J.K. WallWhat a tough week for Lilly. On Aug. 12, a judge struck down the Indianapolis-based drugmaker’s U.S. patent on Strattera,
which might cost the company about $450 million in annual revenue. Then, five days later, Lilly halted clinical trials on
one
of its experimental Alzheimer’s medicines, because patients did worse on the drug than on a placebo.
MoreLilly's Cymbalta helps chronic pain in U.S. review
August 17, 2010
Bloomberg NewsApproval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta's
annual sales.
MoreLilly halts development of Alzheimer's drug
August 17, 2010
IBJ Staff and Associated PressStudies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
MoreLilly braces for plunge in profits
August 14, 2010
J.K. WallIndianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of
loss of revenue that it's hard to picture what the company will look like in five years.
MoreLife sciences panel pegs bright spots in Indiana
August 14, 2010
Leaders tackle issues ranging from research to cold storage to the future of Eli Lilly and Co.
MoreEli Lilly loses patent lawsuit for Strattera
August 13, 2010
IBJ Staff and Associated PressEli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention
deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
MoreFor Lilly, it's a big one that got away
August 11, 2010
J.K. WallAn experimental medicine for hepatitis C that Lilly helped identify and develop is now on the cusp of market approval, with
analysts predicting as much as $2 billion in annual U.S. sales.
MoreCourt defeat lost in Lilly's gloomy long-term outlook
August 9, 2010
J.K. WallEli Lilly and Co.'s loss of a patent on one of its blockbuster drugs in court late last month received a collective yawn
from
investors, who have shunned the stock because of five looming patent expirations.
MoreLilly among bidders for Denmark company, source says
July 30, 2010
Bloomberg NewsCopenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said.
Ascendis may choose a final bidder by early September.
MoreLilly loses appeal over patent for cancer drug Gemzar
July 28, 2010
IBJ Staff and Bloomberg NewsA U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013.
Gemzar generated $1.36 billion in global sales in 2009.
MoreLilly's second-quarter profits surge 16 percent
July 22, 2010
J.K. WallIndianapolis-based drugmaker Eli Lilly and Co. recorded profits of $1.3 billion, or $1.22 per share, during the three months
ended June 30,
even after paying $27 million in severance to laid off employees.
MoreLilly completes $180 million acquisition of Alnara
July 21, 2010
Massachusetts-based Alnara Pharmaceuticals Inc. is a privately held company
developing an enzyme-replacement therapy for disorders of the pancreas.
MoreNew rules raise stakes for Lilly drug
July 21, 2010
J.K. WallDrugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week
when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses
of the disease.
MoreLilly reveals plans to cut 340 IT jobs
July 15, 2010
J.K. WallThe Indianapolis-based drugmaker eliminated 140 information technology jobs in June through retirements, resignations and
some cuts. Another 115
cuts will be made this month, and the remainder by the end of the year.
MoreLilly, Roche dive deep into diagnostics
July 14, 2010
J.K. WallTwo Indianapolis giants—Eli Lilly and Co. and Roche Diagnostics—are working hard to pair up drugs and diagnostic
tests to gin up more sales.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
The Fringe! Plus, the simple fact that there are so many local faves in such close proximity to each other.
I remenber, watching the toll road, being built, through South Bend, when I was 10 years old. I believe, back then that it was estimated, that the toll road, would be paid for in 20 years and then it would be free. I am now 71, what happened? Since the power is in the people, by that, I mean that, we the people are in total control of everything. I, suggest that no one ever use the toll road again, let it go broke. We the people can control the price of everything, from groceries to gas, if we would just do it. If we don't pay the asking price, the sellers will lower the price and if we wait awhile, they will lower the price to what we accept as reasonable. I would like to know why a highway like interstate 94, is so well maintained, a much better highway, than the toll road, but has no tolls. I would also like to know why, a sitting governor, with a term limit, maximum of eight years, can lease, public property, for 75 years. Even though I have transponders in both of my trucks and will not be affected by the increase, I have been and will contine to avoid using the toll road. I make many trips from northern Indiana to Chicago, every year, and I prefer the better highway, I94!
Coming from her background,she should be used to those kinds of advances! Menard probably figured it was ok to tuck a buck!
I'm still waiting for the list of available, high quality apartments in the Village.
This criminal masquerading as a lawyer obviously has serious issues. He’s been proven by his own testimony to be a pathological liar and probably has a personality disorder as he seems to be constructing a reality around himself. He places no value on truth, honesty or loyalty as evidenced by what he has done to his clients and his own family. And by the demands and lies he has made in court, it is evident he feels entitled to do and say whatever suits his purpose and everyone else is expected to nod obediently and believe him because he is, after all, Bill Super Lawyer; or BS lawyer for short. This millionaire wanna-be no longer owns anything of value; he squandered it and put everything he had into foreclosure. He has no money, house, car, boat or vacation home left to show for what he earned or what he stole. He’s just another loser without morals who will be doing time. I’m certain all of his courtroom shenanigans are antagonizing his poor victims. As Lamar said, his behavior and claims in court have been outrageous. The judge needs to be more than concerned; he needs to be judicial and end this nonsense.